LY294002

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

For research use only.

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

LY294002 Chemical Structure

CAS No. 154447-36-6

Selleck's LY294002 has been cited by 1473 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Targets
CK2 [5]
(Cell-free assay)
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
DNA-PK [6]
(Cell-free)
98 nM 0.5 μM 0.57 μM 0.97 μM 1.4 μM
In vitro

LY294002 is not exclusively selective for the PI3Ks, and could in fact act on other lipid kinases and additional apparently unrelated proteins. LY294002 is shown to inhibit not only mTOR and DNA-PK, but also other protein kinases, such as CK2 (casein kinase 2) and Pim-1[5]. LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 cells MVjGeY5kfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKEircz30ZYdo\WRiYn;2bY5mKFCLM1ug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0yOCEQvF2u MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODl7OEO1NUc,OTB7OUizOVE9N2F-
HeLa cells NEfw[WZDcW6maX7nJIFn\mmwaYT5JIF{e2G7 MmHXRolv\GmwZzDh[oZqdmm2eTDmc5IhWEl|LXvpcoF{\SCrc3;sZZRm\CCocn;tJGhmVGFiY3XscJMtKEurPU[g{txO NIrWbYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[1PFg4OCd-MUW2OVg5PzB:L3G+
HeLa cells MkLUSpVv[3Srb36gZZN{[Xl? NUG5RXVmUW6qaXLpeIlwdiCxZjDtWG9TKHC{b4TlbY4hcXOxbHH0[YQh\nKxbTDI[WxiKGOnbHzzMEBKSzVyPUKuOUDPxE1w M{nIdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFcxLz5zNU[1PFg4ODxxYU6=
HeLa (human carcinoma) cells. NH2wO5JHfW6ldHnvckBie3OjeR?= MVLJckB3cXS{bzDpcohq[mm2aX;uJI9nKESQQT3k[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2VqRF7BMXBMMSCocn;tJGhmVGFiKHj1cYFvKGOjcnPpco9u[SliY3XscJMtKEmFNUC9NU41KM7:TT6= NGfhWpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[1PFg4OCd-MUW2OVg5PzB:L3G+
human PC3 cells NVWxdok6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NFzZZ44zPSEQvF2= M2TKTVEzOCCq NUTo[lAySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZQhOjVidV2gZYZ1\XJiMUKwJIhzeyCkeTDNWHQh[XO|YYmgdoVt[XSrdnWgeI8hTE2VTx?= MmfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4OECxOVkoRjF4NkiwNVU6RC:jPh?=
human BJ cells MoTVSpVv[3Srb36gZZN{[Xl? NV\qdWFtOjVizszN NF;zNW0zKGh? MkXXRYN1cX[jdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHH0JHRpejNyODDpckBRTEeILYP0bY12dGG2ZXSgd4VzfW1ic4ThdpZm\CCqdX3hckBDUiClZXzsd{BifCB{NTD1UUB1emWjdHXkJFIhcHK|IHLl[o9z\SCSRFfGJINp[WyuZX7n[UBjgSCrbX31co9jdG:2dHnu[y=> M{jpXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O|A5PTxxYU6=
human BJ cells NHnXZnRHfW6ldHnvckBie3OjeR?= MYeyOUDPxE1? MnX0NkBp NU\QZoZFUW6qaXLpeIlwdiCxZjDQTVNMKHOrZ37hcIlv\yCrbjDQSGdHNXO2aX31cIF1\WRic3XyeY0he3Sjco\l[EBpfW2jbjDCTkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDsZZNucWRiRVfGVE9RUCCmb33hbY4hd2ZiQXv0JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHBJNUWJRmCgdoVlcXO2cnnieZRqd25idH:gdIxie22jIH3lcYJz[W6nIHH0JFI2KHWPIITy[YF1\WRiMjDodpMh[mWob4LlJHBFT0ZiY3jhcIxmdmenIHL5JINwdm[xY3HsJI1q[3Kxc3PvdJk> M4LFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O|A5PTxxYU6=
mouse mast cells M{T0bmZ2dmO2aX;uJIF{e2G7 MV2yNEDPxE1? M{XkW2lvcGmkaYTpc44hd2ZiU1PGMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gcY92e2VibXHzeEBk\WyuczDheEAzOCEQvF2= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd6OUe0Nkc,OTZ5OEm3OFI9N2F-
THP1 cells NEjrUoxHfW6ldHnvckBie3OjeR?= NFPTc|JKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBkcGWvb4ThfIl{KG:oIGTIVFEh[2WubIOsJGlEPTB;M{eg{txONg>? NFnLSG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke4PVc1Oid-MU[3PFk4PDJ:L3G+
mouse Raw264 macrophage M3ntUmZ2dmO2aX;uJIF{e2G7 MmXkTY5pcWKrdHnvckBw\iCFNXGtcYVlcWG2ZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gcY92e2ViUnH3NlY1KG2jY4LvdIhi\2VuIFnDOVA:OTBizszNMi=> NXnlc21zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3PFk4PDJpPkG2O|g6PzR{PD;hQi=>
THP1 cells MkW3SpVv[3Srb36gZZN{[Xl? MkfyTY5pcWKrdHnvckBw\iCPQ2CxMYlv\HWlZXSgVGtDN0GtdDDwbI9{eGixconsZZRqd25iaX6gWGhROSClZXzsd{whUUN3ME2xMlY2KM7:TT6= M3LS[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{i5O|QzLz5zNke4PVc1OjxxYU6=
THP1 cells NWLYfndGTnWwY4Tpc44h[XO|YYm= NUjPU4YyUW6qaXLpeIlwdiCxZjDTR2YyNWmwZIXj[YQhWEuEL1HreEBxcG:|cHjvdplt[XSrb36gbY4hXEiSMTDj[YxteyxiSVO1NF0yNjBzIN88UU4> NH;HN4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke4PVc1Oid-MU[3PFk4PDJ:L3G+
human A375 cells MV3Qdo9tcW[ncnH0bY9vKGG|c3H5 M1nMUVQ3KGh? MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiYX\0[ZIhPDZiaILzMEBKSzVyPUiuOEDPxE1w M4nrb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MES5NlQ5Lz5zN{C0PVI1QDxxYU6=
HeLa cells MlrtSpVv[3Srb36gZZN{[Xl? MmfwTY5pcWKrdHnvckBw\iCDWD23OVA{KGKrbnTpcochfG9icnXjc41jcW6jboSgVIxsOyCneIDy[ZN{\WRiaX6gTIVN[SClZXzsd{BjgSCZZYP0[ZJvKGKub4SsJGlEPT1|IN88UU4> NF32PXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GzOVI1QCd-MUexN|UzPDh:L3G+
human SW480 cells MWXGeY5kfGmxbjDhd5NigQ>? NILBbpUzOCEQvF2= MVWyOEBp M2HhS2Rm[3KnYYPlJIlvKHO3co\peolvKGW6cILld5Nqd25iaX6gbJVu[W5iU2e0PFAh[2WubIOgZZQhOjBidV2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZY5idHm|aYO= NXHNblBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0O|I6PjJpPkG3OFczQTZ{PD;hQi=>
human A375 cells NFnmPWhRem:uaX\ldoF1cW:wIHHzd4F6 NHj3VnRKdmirYnn0bY9vKG:oIIPldpVuNWmwZIXj[YQheHKxbHnm[ZJifGmxbjDv[kBpfW2jbjDBN|c2KGOnbHzzMEBKSzVyPUiuOEDPxE1w NIG5TnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNVc{QSd-MUe2NFE4Ozl:L3G+
human A2780 cells M3;BeWFxd3C2b4Ppd{Bie3OjeR?= NV\iSlQ5OiEQvF2= MoHYNVIhcA>? M1HkUmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gZ4l{eGyjdHnuMZJme2m|dHHueEBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDa4SgcIV3\WxiYYSgNkB2VSCjZoTldkAyOiCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqey5? MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6NECxPEc,OTd4OESwNVg9N2F-
human H4 cells NUexdGo1TnWwY4Tpc44h[XO|YYm= NXv3WnRxOiCq NUK3S5cyTGWlcnXhd4UhcW5iRmnWSU1TTlBtII\ld4lkdGViaX70[Y5{cXS7IIDldkBk\WyuIHnuJIh2dWGwIFi0JINmdGy|IHHmeIVzKDJiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> M2ixTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEK0OVg1Lz5zOECyOFU5PDxxYU6=
Sf9 cells M33ZcmZ2dmO2aX;uJIF{e2G7 M3ztbmlvcGmkaYTpc44hd2ZiQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVA:Pi57IN88UU4> M4rJ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{KxO|E3Lz5zOEOyNVcyPjxxYU6=
rat RBL2H3 cells MWPGeY5kfGmxbjDhd5NigQ>? MnHNTY5pcWKrdHnvckBw\iCDMkOxPFcucW6mdXPl[EBl\We{YX71cIF1cW:wIHnuJJJifCCUQlyyTFMh[2WubIO= MnK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|Mki3NVYoRjF6M{K4O|E3RC:jPh?=
human U87MG cells NF;jc2FHfW6ldHnvckBie3OjeR?= NWfh[IV6UW6qaXLpeIlwdiCxZjDHV2s{NWKndHGgbY4hcHWvYX6gWVg4VUdiY3XscJMh[nliRVzJV2EtKEmFNUC9PE4yKM7:TT6= M1G4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{S1OlA6Lz5zOEO0OVYxQTxxYU6=
human H460 cells MkTCSpVv[3Srb36gZZN{[Xl? NEnkS4U{OCEQvF2= NYTGS2psUW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKEh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYKgOFc{KHWyIITvJFMxKHWP MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDVyMU[wNUc,OTh3MEG2NFE9N2F-
human U251HRE cells M4XFeGZ2dmO2aX;uJIF{e2G7 MnHnTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMTDhZ5RqfmG2aX;uJIlvKGi3bXHuJHUzPTGKUlWgZ4VtdHNiYomgZ4VtdCCkYYPl[EBz\XCxcoTldkBo\W6nIHHzd4F6 M4rz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUCxOlAyLz5zOEWwNVYxOTxxYU6=
human 184B5 cells NXry[ZlGS3m2b4TvfIlkyqCjc4PhfS=> MmDmR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVg1SjViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTN7LkO3JO69VS5? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ7MUi5OEc,OTh4OUG4PVQ9N2F-
human MDA-MB-468 cells NEPvc5JEgXSxdH;4bYPDqGG|c3H5 Mnm5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDifUBUWkJiYYPzZZktKEmFNUC9NVAvPCEQvF2u MmfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4OUG4PVQoRjF6NkmxPFk1RC:jPh?=
human MDA-MB-468 cells M3jjSGN6fG:2b4jpZ:Kh[XO|YYm= MYnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD16LkKg{txONg>? NILGS5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
MDA-MB-231 cells MWHDfZRwfG:6aXRCpIF{e2G7 MmeyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9Ok44OSEQvF2u M1rVUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-468 cells NXzLUI1KS3m2b4TvfIlkyqCjc4PhfS=> NXH1SVBiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSClaHzvdo9yfWmwZTDifUBUWkJiYYPzZZnwxIxiSVO1NF01Njd4IN88UU4> NX3mcppJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MDA-MB-231 cells NYPQcVN6S3m2b4TvfIlkyqCjc4PhfS=> MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD12LkO1JO69VS5? M4mzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MDA-MB-231 cells MojSR5l1d3SxeHnjxsBie3OjeR?= M1HHbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiMkCg{txOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4PhfUwhT0l;Mz6zNkDPxE1w M4HDdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells NVe0NXZOS3m2b4TvfIlkyqCjc4PhfS=> M3vKe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[nliU2LCJIF{e2G7LDDHTV0{NjF4IN88UU4> M1j4U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NkmxPFk1Lz5zOE[5NVg6PDxxYU6=
human MCF7 cells M3[wPGN6fG:2b4jpZ:Kh[XO|YYm= M3LtSmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNVAhfU1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSUWwQVMvODhizszNMi=> NUP5T3A6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2PVE5QTRpPkG4OlkyQDl2PD;hQi=>
human MCF7 cells MmHpR5l1d3SxeHnjxsBie3OjeR?= M1zycGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNlAh|ryPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjZ|IN88UU4> NHzxeZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[5NVg6PCd-MUi2PVE5QTR:L3G+
Sf21 cells MmHtSpVv[3Srb36gZZN{[Xl? NVXjVZU4UW6qaXLpeIlwdiCxZjDtc5V{\SC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|LXnu[oVkfGWmIGPmNlEh[2WubIOsJGlEPTB;MD61JO69VS5? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEK2PUc,OTl5NEiyOlk9N2F-
Sf9 cells Mnf1[ox2d3Knc3PlcpQheG:uYYLpfoF1cW:wIHHzd4F6 MYDJcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy|IHL5JIZtfW:{ZYPj[Y51KHCxbHHybZpifGmxbjDhd5NigQ>? M{DtS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUKxOlMyLz5{MUGyNVY{OTxxYU6=
Sf9 cells NF\KcItHdHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? M1fse2lvcGmkaYTpc44hd2ZiaIXtZY4hWEl|S3HsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZpkh\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxRTBwNUWg{txONg>? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF{MU[zNUc,OjFzMkG2N|E9N2F-
human IGROV1 cells MYfGeY5kfGmxbjDhd5NigQ>? NFrmfo4zPCCq MlzpR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTWdTV1ZzIHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBifCCJMTDwbIF{\SCjdDC1JIZwdGRiSVO1NEBi\nSncjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl? NYTpe|JGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human IGROV1 cells MmDISpVv[3Srb36gZZN{[Xl? Mnr6NlQhcA>? M2DRZWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGlIWk:YMTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{GgdIhie2ViYYSgNUBnd2ymIFnDOVAh[W[2ZYKgNlQhcHK|IHL5JIZtd3diY4n0c41mfHK7 MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MU[xOVEoRjJzMkG2NVUyRC:jPh?=
human IGROV1 cells M{fL[WZ2dmO2aX;uJIF{e2G7 MWGyOE81QCCq NYTNd3I2UW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ5lkdGmwIFSxJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJzNkG1NUc,OjF{MU[xOVE9N2F-
human IGROV1 cells M{X6SGZ2dmO2aX;uJIF{e2G7 NFS1ZVgzPC92ODDo MnzETY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCLR2LPWlEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpd3K7bHH0[YQhSUuWIHzleoVtKGG2IEGgeI8hPSC2aX3ld{BKSzVyIHHmeIVzKDJ2IITvJFQ5KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NWO5SIdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVYyPTFpPkKxNlE3OTVzPD;hQi=>
human HCT116 cells Mnr0R5l1d3SxeHnjxsBie3OjeR?= MUW3NkBp NIPBSG1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02Pi5yMTFOwG0v Mn;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEWyOVAoRjJzOUS1NlUxRC:jPh?=
human KB cells M{jWXWN6fG:2b4jpZ:Kh[XO|YYm= Mn7QO|IhcA>? MmixR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD12ND63OkDPxE1w MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2NUK1NEc,OjF7NEWyOVA9N2F-
HUVEC MULGeY5kfGmxbjDhd5NigQ>? M1r5elExNTJ3IN88US=> M4TxUVMxKG2rbh?= NXHhXllTUW6qaXLpeIlwdiCxZjDUUmZidHCqYT3zeIlufWyjdHXkJIh2dWGwIFnDRW0uOSCycn;tc5RmeiCjY4Tpeol1gSCneIDy[ZN{\WRiaX6gTHVXTUNiYYPz[ZN{\WRiYYOgZoV1[S2pYXzhZ5Rwe2mmYYPlJIFkfGm4aYT5JIF1KDFyIITvJFI2KHWPIIDy[ZRz\WG2ZXSg[o9zKDNyIH3pcpMh[mWob4LlJHRPTmGucHjhJINp[WyuZX7n[UBu\WG|dYLl[EBi\nSncjC1JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> MmLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMk[0NVAoRjJ{MEK2OFExRC:jPh?=
HUVEC Mn3mSpVv[3Srb36gZZN{[Xl? NGLJV5oyOC1{NTFOwG0> NYK1NXAxOTZiaB?= MXfJcohq[mm2aX;uJI9nKFSQRnHsdIhiNXO2aX31cIF1\WRiSVPBUU0yKG2UTlGg[ZhxemW|c3nvckBqdiCKVW\FR{BifCBzMDD0c{AzPSC3TTDwdoV1emWjdHXkJIZweiBzNjDodpMh[mWob4LlJHRPTmGucHjhJINp[WyuZX7n[UBu\WG|dYLl[EBi\nSncjC2JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXN? MorQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMk[0NVAoRjJ{MEK2OFExRC:jPh?=
human HCT116 cells MoDaSpVv[3Srb36gZZN{[Xl? MXGxNEDPxE1? M2nuV2lvcGmkaYTpc44hd2ZiQXv0JIV5eHKnc4Ppc44hcW5iaIXtZY4hUEOWMUG2JINmdGy|IHH0JFExKHWPIHL5JIludXWwb3Lsc5Qh[W6jbInzbZM> NIjPeo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells M4XqTWZ2dmO2aX;uJIF{e2G7 M4LjN|ExKM7:TR?= MUnJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCKMUC0O3IhdXW2YX70JIlvKGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGG2IEGwJJVOKGK7IHntcZVvd2Kub4SgZY5idHm|aYO= MkP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells M3\PeWZ2dmO2aX;uJIF{e2G7 M2T6eFExKM7:TR?= NVX6R3FIUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhSWu2IGPldlQ4OyCyaH;zdIhwenmuYYTpc44h[XRiMUCgeW0h[nliaX3teY5w[myxdDDhcoFtgXOrcx?= M4PRSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells MWHGeY5kfGmxbjDhd5NigQ>? NV3XbGJrOTBizszN MWixNEBucW5? MkjDTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiSEGwOFdTKG23dHHueEBqdiCqdX3hckBJS1RzMU[gZ4VtdHNidYPpcochYzN{UG3BWHAh[XRiMUCgeW0h[W[2ZYKgNVAhdWmwcx?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human HCT116 cells NXLEZ4E6TnWwY4Tpc44h[XO|YYm= NGDmdIYyOCEQvF2= NXvXRYg{OTBibXnu MVXJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> NHjLfnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNlczOSd-MkKyNVI4OjF:L3G+
human HCT116 cells MkfRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\aNJk1QCCq NFfVSG5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzMU[gZ4VtdHNib4\ldoV5eHKnc4PpcochWEl|S3HsdIhiKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9Ok44KM7:TT6= MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUK3NlEoRjJ{MkGyO|IyRC:jPh?=
human HCT116 cells M3HZW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYLi[21UPDhiaB?= MV\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME21Mlgh|ryPLh?= M3fzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkGyO|IyLz5{MkKxNlczOTxxYU6=
human HCT116 cells MlvSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnvCOFghcA>? MkPRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KG:4ZYLlfJBz\XO|aX7nJHBKO0ujbIDoZUBJOTB2N2KgcZV1[W62IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PS5|IN88US=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMkeyNUc,OjJ{MUK3NlE9N2F-
human A549 cells NH\MNm9EgXSxdH;4bYPDqGG|c3H5 NIDoVmE4OiCq NWjvTGxIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 NUjacJhURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PFA5PTFpPkKyOFgxQDVzPD;hQi=>
human PC3 cells NVLQPIFDS3m2b4TvfIlkyqCjc4PhfS=> NWrlbW11PzJiaB?= NVHiOlNVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OlEvOzVizszNMi=> NGrWc3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS4NFg2OSd-MkK0PFA5PTF:L3G+
human HL60 cells NInySYJEgXSxdH;4bYPDqGG|c3H5 MX[3NkBp NVnORox[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVkvQTRizszNMi=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR6MEi1NUc,OjJ2OEC4OVE9N2F-
Sf21 cells NF3SeFJHfW6ldHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKG2xdYPlJJdqdGRidInw[UBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NF0xNjVizszN NV\wPJg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
HEK293 cells MXXGeY5kfGmxbjDhd5NigQ>? MYixMlUhcA>? NEPwOYNFcXOybHHj[Y1mdnRib3[gX|NJZUyVRDDmdo9uKGi3bXHuJFVJXDZicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyNjViaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6p NEnQPIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWzO|E2Oyd-MkK1N|cyPTN:L3G+
human H1299 cells NELIdJJHfW6ldHnvckBie3OjeR?= NIXRc4MxNjFvM{Cg{txO MkP0NlQhcA>? MmDwTY5lfWO2aX;uJI9nKEqQSz3t[YRq[XSnZDDDTG9RKGW6cILld5Nqd25iaX6gbJVu[W5iSEGyPVkh[2WubIOgZZQhOC5zIITvJFMxKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NWXzN3lGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2NlIxPjlpPkKyOlIzODZ7PD;hQi=>
human H1299 cells MWPGeY5kfGmxbjDhd5NigQ>? MVewMlEuOzBizszN NVz6eFBNOjRiaB?= M{HTbmlv\HWldHnvckBw\iCGUkWg[ZhxemW|c3nvckBqdiCqdX3hckBJOTJ7OTDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZ{MkC2PUc,OjJ4MkKwOlk9N2F-
human H1299 cells MkPvSpVv[3Srb36gZZN{[Xl? NI\qXosxNjFvM{Cg{txO MXiyOEBp MXzEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCxNFAhfWdxbXygWHJCUUxiYX7kJHBKO0tiaX7obYJqfG:{IFzZNlk1ODB{ NFzPUZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[yNlA3QSd-MkK2NlIxPjl:L3G+
human H1299 cells NV\hNJF1TnWwY4Tpc44h[XO|YYm= M2LIVlAvOS1|MDFOwG0> NVO2fog6OjRiaB?= NUT0bFVYTG:5bjDy[Yd2dGG2aX;uJI9nKGOLQWCyJIV5eHKnc4Ppc44hcW5iaIXtZY4hUDF{OUmgZ4VtdHNiYYSgNE4yKHSxIEOwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? Mnz0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkKwOlkoRjJ{NkKyNFY6RC:jPh?=
MDA-MB-231 cells MmnRR4VtdCCrbo\hd4lwdiCjc4PhfS=> MnHrNlQhcA>? NHrQOI9KdmirYnn0bY9vKG:oIHXwbZRp\WyrYXyg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGOnbHygcYloemG2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgdJJmNWmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JINmdGxiaX72ZZNqd25iYYPzZZktKEmFNUC9NE4{QCEQvF2u NX3oR2c{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFQyODhpPkKyPFA1OTB6PD;hQi=>
human LNCAP cells NFrWdZFHfW6ldHnvckBie3OjeR?= NGnzUmQxNjFvM{Cg{txO M4izR|I1KGh? MVTEc5dvemWpdXzheIlwdiCxZjDzeZJ3cX[rbjDlfJBz\XO|aX;uJIlvKGi3bXHuJGxPS0GSIHPlcIx{KGG2IECuNUB1dyB|MDD1UUBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NXzqOFcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|I{OTZpPkKyPFMzOzF4PD;hQi=>
human LNCAP cells NHLEcoZHfW6ldHnvckBie3OjeR?= M33mflAvOS1|MDFOwG0> M4jZclMxKG2rbh?= MmTITY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6M{KzNVYoRjJ{OEOyN|E3RC:jPh?=
human PC3 cells NUW3RmUxTnWwY4Tpc44h[XO|YYm= M{\uS|UxKM7:TR?= M{Dte|ghcA>? MkHXTY5lfWO2aX;uJI9nKHB{MTDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gVGM{KGOnbHzzJIF1KDVyIIXNJIlv[3WkYYTl[EBnd3JiODDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= Mn60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OUi0O|IoRjJ{OUm4OFczRC:jPh?=
human BT474 cell MkDhVJJwdGmoZYLheIlwdiCjc4PhfS=> NFrNSnM4OiCq M2nwUmlvcGmkaYTpc44hd2ZiaIXtZY4hSlR2N{SgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYRvwKwhUUN3ME2yNE44KM7:TT6= NXjQendLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVAxODVpPkKzOFExODB3PD;hQi=>
human PC3 cell NFy5fYhRem:uaX\ldoF1cW:wIHHzd4F6 M{HCXlczKGh? NWTEPXQxUW6qaXLpeIlwdiCxZjDoeY1idiCSQ{OgZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;MUKuNUDPxE1w MljEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ|NEGwNFA2RC:jPh?=
human PC3 cells NVWydXFtTnWwY4Tpc44h[XO|YYm= NVvlPHo4OzBibXnu MVTJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhe2W{aX7lJFQ4OyCjZoTldkA{OCCvaX7zJIJ6KEWOSWPBMEBKSzVyPUGuN:69VS5? MojWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUCwNFUoRjJ|NEGwNFA2RC:jPh?=
human MGC803 cells NGD2WGlHfW6ldHnvckBie3OjeR?= M3\h[FI2KM7:TR?= NFT0W3g1QCCq M4LyT2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJG1ISzhyMzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG|ZTDheEAzPSC3TTDh[pRmeiB2ODDodpMhfXOrbnegdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDh[pRmeiB2ODDodpMh[nliZnzve{BkgXSxbXX0[ZIhemWuYYTpeoUhfG9iY3;ueJJwdA>? NIDhT5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxPVg3QSd-MkSxNVk5Pjl:L3G+
mouse RAW264.7 cells M134[2Z2dmO2aX;uJIF{e2G7 NEDuUm8zPSEQvF2= NXPE[Y1iOjBiaB?= NHfK[HNKdmirYnn0bY9vKG:oIGDJN2swSUuWIHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiaV7PV{Bxem:2ZXnuJIV5eHKnc4Ppc44h[XRiMkWg{txOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NVf2cZUzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVk3OTZpPkK0Nlk6PjF4PD;hQi=>
human A549 cells M2fPcHBzd2yrZnXyZZRqd25iYYPzZZk> MVm3NkBp NYTxfHc4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUiyMlMzKM7:TT6= NGKyUZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HuH7 cells NYDY[5E2WHKxbHnm[ZJifGmxbjDhd5NigQ>? NFftPY84OiCq NHfDfmhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFj1TFch[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NkeuNVgh|ryPLh?= NYPmT3Y5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVM4QDdpPkK1Olk{Pzh5PD;hQi=>
human HCT116 cells NFnzVoFRem:uaX\ldoF1cW:wIHHzd4F6 MlTHO|IhcA>? Ml7NRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NUGuPFIh|ryPLh?= NFj3NHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[5N|c5Pyd-MkW2PVM4QDd:L3G+
human HL60 cells NYTqe21ZWHKxbHnm[ZJifGmxbjDhd5NigQ>? NYHOPVdLPzJiaB?= M2nTRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOD60N{DPxE1w NWK2[XQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVM4QDdpPkK1Olk{Pzh5PD;hQi=>
Sf9 cells Mn7GSpVv[3Srb36gZZN{[Xl? NFHX[XJKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgbJVu[W5iQ1uyJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNuIFnDOVAhRSB4Lkmg{txONg>? M2XCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyOUm4N|UyLz5zMEm5PFM2OTxxYU6=
HeLa cells NHLhbWNHfW6ldHnvckBie3OjeR?= MUfJckB3cXS{bzDpcohq[mm2aX;uJI9nKESQQT3k[ZBmdmSnboSgdJJwfGWrbjDrbY5ie2VqRF7BMXBMMSCocn;tJGhmVGFiKHj1cYFvKGOjcnPpco9u[SliY3XscJMvNCCLQ{WwJF0hOS52IN88UU4> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjl2MUOzPUc,OTJ7NEGzN|k9N2F-
HeLa cells Mn3LSpVv[3Srb36gZZN{[Xl? NIC1XFVKdmirYnn0bY9vKG:oIFTORUBl\XCnbnTlcpQheHKxdHXpckBscW6jc3WgbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxKD1iMT61JO69VS5? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZ3OEi3NEc,OTV4NUi4O|A9N2F-
Sf21 cells NE\tXWJHfW6ldHnvckBie3OjeR?= NFfO[odKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2ey2rbn\lZ5Rm\CCVZkKxJINmdGy|LDDJR|UxKD1iMD65JO69VS5? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2OEK2PUc,OTl5NEiyOlk9N2F-
Sf21 cells NV7NS2w5TnWwY4Tpc44h[XO|YYm= NWfVe4NYUW6qaXLpeIlwdiCxZjDic5ZqdmVicnXjc41jcW6jboSgVGk{U2ejbX3hJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lIyKGOnbHzzMEBKSzVyIE2gO{DPxE1w M3\USlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S4NlY6Lz5zOUe0PFI3QTxxYU6=
HeLa cells M4iwZ2Z2dmO2aX;uJIF{e2G7 NG[2RnNC[3Srdnn0fUBifCCSSUPLJIlvKGi3bXHuJGhmVGFiY3XscJMh[nliRVzJV2EtKEWFNUCgQUAyNjVizszNMi=> NELQNFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC5NlMzOyd-MkCwPVI{OjN:L3G+
Sf21 cells NFqxU4ZHfW6ldHnvckBie3OjeR?= NHS5TYdKdmirYnn0bY9vKG:oIGDJN2tl\Wy2YTDlfJBz\XO|ZXSgbY4h[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NEA:KDBwNUeg{txONg>? NVG0OoE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NlA3OzBpPkKyOVIxPjNyPD;hQi=>
Sf21 cells NV71SVh3TnWwY4Tpc44h[XO|YYm= M{jmUmlvcGmkaYTpc44hd2ZiaIXtZY4hf2muZDD0fZBmKFCLM1vi[ZRiKGW6cILld5Nm\CCrbjDT[lIyKGOnbHzzJINwNWW6cILld5NqdmdiTj30[ZJucW6jbDDIbZMufGGpZ3XkJIh2dWGwIIC4OYEhfXOrbnegUE1idHCqYT3wbI9{eGijdHnkfYxqdm:|aYTvcEB{fWK|dILheIUh[nliVFzDJIJie2WmIIDoc5NxcG:{IHntZYdqdmduIFnDOVAhRSByLkm3JO69VS5? M4jkUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUKwOlMxLz5{MkWyNFY{ODxxYU6=
HL60 cells MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUWwbVRNOyCmYYnz M1[0bGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDt[YF{fXKnZDDh[pRmeiB|IHThfZMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMUSg{txONg>? MmLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NEWxNVAoRjJ4OUS1NVExRC:jPh?=
U937 cells MnHiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVLkUJdZOyCmYYnz Mo\mRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOUO3JINmdGy|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSBzNDFOwG0v MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl2NUGxNEc,OjZ7NEWxNVA9N2F-
Jurkat cells MkLRRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M{n4eVMh\GG7cx?= NYntfXFQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDKeZJs[XRiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgN{Bl[Xm|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFIzKM7:TT6= NYXF[G1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OFUyOTBpPkK2PVQ2OTFyPD;hQi=>
K562 cells Mlj0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVT3[FVVOyCmYYnz MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDN6IN88UU4> M4jmWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OUS1NVExLz5{Nkm0OVEyODxxYU6=
U266 cells NUXsdolISW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MX6zJIRigXN? MkPERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXMk[2JINmdGy|IH3lZZN2emWmIHHmeIVzKDNiZHH5d{BjgSCPVGOgZZN{[XluIFnDOVAhRSB2NjFOwG0v MkPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NEWxNVAoRjJ4OUS1NVExRC:jPh?=
MDA-MB-231 cells NGHKWoNCdnSrbXnndoF1d3K7IHHzd4F6 MXqyOEBpenN? M2X0UWFvfGmvaXfyZZRwenliYXP0bZZqfHliYXfhbY5{fCCHR1[gbY5lfWOnZDDjbIVud3SjeHnzJIlvKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyOEBpenNiZn;scI94\WRiYomgSWdHKGGmZHn0bY9vKG[xcjCzMlUhcHK|IHL5JIxq\2i2IH3pZ5Jwe2OxcImsJGlEPTBiPTCwMlM5KM7:TT6= NVLYVoZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1PVgzOzdpPkK3OVk5OjN5PD;hQi=>
MDA-MB-231 cells MnLyRY51cWmwdnHzbZZmKGG|c3H5 MXmzMlUhcHK| NWH3OI9PSW62aXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDj[YxtKGmwdnHzbY9vKGGodHXyJFMvPSCqcoOsJGlEPTBiPTCwMlM5KM7:TT6= NYHVcHJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwNFk2OjFpPkK4NFA6PTJzPD;hQi=>
HEK293T cells MXLGeY5kfGmxbjDhd5NigQ>? MVGxJIhz M2q1R2lvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2KndHGgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDpcoN2[mG2ZXSg[o9zKDFiaIKgZpkhVENvTWOvUXMh[W6jbInzbZMtKEmFNUCgQUAxNjR{IN88UU4> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
HEK293T cells MnTGSpVv[3Srb36gZZN{[Xl? NXXSS|ZDOSCqch?= M13HW2lvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2SnbIThJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgbY5kfWKjdHXkJIZweiBzIHjyJIJ6KEyFLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOS53MzFOwG0v NHjiO5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
HEK293T cells MV;GeY5kfGmxbjDhd5NigQ>? NIX0Wm8yKGi{ M1e1TmlvcGmkaYTpc44hd2ZiaX3tc4JqdGm8ZXSgUk1NYTJ7NECwNkBj\WGmIHLpcoRqdmdidH:gVGk{U2GucHjhJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N3Qh[2WubIOgbY5kfWKjdHXkJIZweiBzIHjyJIJ6KEyFLV3TM21UKGGwYXz5d4l{NCCLQ{WwJF0hOi5|NzFOwG0v NH\yUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
MDA-MB-231 cells NVvHdXNxTnWwY4Tpc44h[XO|YYm= MmrpTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDpcpZie2mxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOzhizszNMi=> Ml\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MEK0NFEoRjJ6M{CyOFAyRC:jPh?=
MCF7 cells MnXySpVv[3Srb36gZZN{[Xl? MnSzNVAhfU1? NHjCdZYyKGi{ MkHFTY5pcWKrdHnvckBw\iCLR1[xVkBxcG:|cHjvdplt[XSrb36gZZQhXHm{MUG2NUBz\XOrZIXlJIlvKGi3bXHuJG1ETjdiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNUBpeiCkeTDIc4VkcHO2IEOzNlU5KHO2YXnubY5oKGKjc3XkJIludXWwb3jpd5Rw[2inbXnjZYwh[W6jbInzbZM> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
SKOV3 cells NHrDe|FHfW6ldHnvckBie3OjeR?= MlPuNlAhfU1? MWqyOEBpenN? NXvE[lc2UW6qaXLpeIlwdiCxZjDCSG5HNWmwZIXj[YQhcW64YYPpc44hcW5iaIXtZY4hW0uRVkOgZ4VtdHNiYYSgNlAhfU1iYX\0[ZIhOjRiaILzJIlvKGK7IH3heJJq\2WuIHnueoF{cW:wIHHzd4F6 M37IRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUKyOFg1Lz5{OUGyNlQ5PDxxYU6=
SKOV3 cells MUjBcpRqdWmpcnH0c5J6KGG|c3H5 NIm0dZczOCC3TR?= MnrUNlQhcHK| NHO1fpJCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCERF7GMYlv\HWlZXSgZ4VtdCCvaXfyZZRqd25iYYSgNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KHOlcnH0Z4ghf2:3bnSgbIVidGmwZzDhd5NigQ>? Mo\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMkK0PFQoRjJ7MUKyOFg1RC:jPh?=
NB1643 cells NUDsNFFleUiWUzDhd5NigQ>? NVvjU|VReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> M{fRU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 cells M1rabJFJXFNiYYPzZZk> M1vqOJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= M13jNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 cells MlfNdWhVWyCjc4PhfS=> NHPaVopyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=> MkTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC cells MV7xTHRUKGG|c3H5 M2TWe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz M3;JOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
J774 cells MVLBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NHryfZEzPCCqcoO= MkO1RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBud3W|ZTDKO|c1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDMVHMucW6mdXPl[EBOS1BzIHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hOy55IN88UU4> MlLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5Mk[2PFAoRjJ7N{K2OlgxRC:jPh?=
J774 cells NIT2S3BCdnSraX7mcIFudWG2b4L5JIF{e2G7 M1K0ZlI1KGi{cx?= M3vwWGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gUHBUNWmwZIXj[YQhUUx4IHX4dJJme3Orb36gZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPS5zIN88UU4> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd{Nk[4NEc,Ojl5Mk[2PFA9N2F-
J774 cells M1HyUmFvfGmrbn\sZY1u[XSxcomgZZN{[Xl? M2jONFI1KGi{cx?= NE\vTHpCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJGo4PzRiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGxRWy2rbnT1Z4VlKG6rdILpZ{BwgGmmZTDwdo9lfWO2aX;uJIFnfGW{IEK0JIhzeyCkeTDHdolme3NiYYPzZZktKEmFNUCgQUA5NjlizszNMi=> M{L3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{K2OlgxLz5{OUeyOlY5ODxxYU6=
J774 cells MVXGeY5kfGmxbjDhd5NigQ>? MXexNEB2VQ>? MX[0JIhzew>? MoKwTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDtc5V{\SCMN{e0JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCOUGOtbY5lfWOnZDDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{BifCBzMDD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NH\W[mg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUeyOlY5OCd-Mkm3NlY3QDB:L3G+
Assay
Methods Test Index PMID
Western blot E-cadherin / p-Akt / Akt ; beta-catenin / p-GSK3β / Cyclin D1 ; Bcl-xl / Bax / caspase3 / cleaved caspase-3 ; p-p70S6K (T389) / p-GSK3β(S9) / pERK / Vinculin ; pPKB-S473 29731993 25344912 23251002 20649566
Growth inhibition assay Cell viability 25344912
Immunofluorescence α-SMA / CD31 ; E-cadherin / beta-catenin ; COX-2 / p-NFκB ; FOXO3a 27671604 29731993 18388194
ELISA IL-10 / IL-1β / TNFα / IL-6 22208359
In vivo

LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol (from reference)

Kinase Assay:

[4]

  • kinase assays:

    PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.

Cell Research:

[2]

  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method:

    1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.

Animal Research:

[3]

  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+ 40%PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.

3mg/mL

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02337309 Terminated Drug: SF1126 Neuroblastoma New Approaches to Neuroblastoma Therapy Consortium|SignalRX Pharmaceuticals Inc.|University of Southern California July 9 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I want to buy a inhibitor that can inactivates Akt/PI3K. I notice the protocol of LY294002 (catalog no. s1105) says it will inactivates Akt/PKB. Is LY294002 available for Akt/PI3K inhibition?

Answer:
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively. It can inhibit PI3K/AKT. PKB is the alternative name of AKT.

Question 2:
What is the suggested formulation of this compound for mouse injection(i.p.)?

Answer:
It can be dissolved in 4% DMSO/30% PEG 300/5% Tween 80/ddH2O at 5 mg/ml clearly, and the concentration of DMSO is safe for in vivo experiments.

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor